6MAM image
Entry Detail
PDB ID:
6MAM
Title:
Cleaved Ebola GP in complex with a broadly neutralizing human antibody, ADI-15946
Biological Source:
PDB Version:
Deposition Date:
2018-08-28
Release Date:
2019-03-20
Method Details:
Experimental Method:
Resolution:
4.10 Å
R-Value Free:
0.28
R-Value Work:
0.26
R-Value Observed:
0.26
Space Group:
P 43 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:ADI-15946 Fab Heavy Chain
Chain IDs:A, C, E
Chain Length:242
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:ADI-15946 Fab Light Chain
Chain IDs:B, D, F
Chain Length:216
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Envelope glycoprotein
Chain IDs:G, I, K
Chain Length:234
Number of Molecules:3
Biological Source:Zaire ebolavirus (strain Mayinga-76)
Polymer Type:polypeptide(L)
Description:Envelope glycoprotein
Chain IDs:H, J, L
Chain Length:110
Number of Molecules:3
Biological Source:Zaire ebolavirus (strain Mayinga-76)
Ligand Molecules
Primary Citation
Structural basis of broad ebolavirus neutralization by a human survivor antibody.
Nat. Struct. Mol. Biol. 26 204 212 (2019)
PMID: 30833785 DOI: 10.1038/s41594-019-0191-4

Abstact

The structural features that govern broad-spectrum activity of broadly neutralizing anti-ebolavirus antibodies (Abs) outside of the internal fusion loop epitope are currently unknown. Here we describe the structure of a broadly neutralizing human monoclonal Ab (mAb), ADI-15946, which was identified in a human survivor of the 2013-2016 outbreak. The crystal structure of ADI-15946 in complex with cleaved Ebola virus glycoprotein (EBOV GPCL) reveals that binding of the mAb structurally mimics the conserved interaction between the EBOV GP core and its glycan cap β17-β18 loop to inhibit infection. Both endosomal proteolysis of EBOV GP and binding of mAb FVM09 displace this loop, thereby increasing exposure of ADI-15946's conserved epitope and enhancing neutralization. Our work also mapped the paratope of ADI-15946, thereby explaining reduced activity against Sudan virus, which enabled rational, structure-guided engineering to enhance binding and neutralization of Sudan virus while retaining the parental activity against EBOV and Bundibugyo virus.

Legend

Protein

Chemical

Disease

Primary Citation of related structures